PF 6753512

Drug Profile

PF 6753512

Alternative Names: PF-06753512; PF-6753512; PrCa VBIR

Latest Information Update: 01 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Pfizer
  • Class Antineoplastics; Cancer vaccines; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Colony stimulating factor receptor antagonists; Cytotoxic T-lymphocyte antigen 4 inhibitors; Fms-like tyrosine kinase 3 inhibitors; Immunomodulators; Interleukin 2 stimulants; Platelet derived growth factor alpha receptor antagonists; Platelet-derived growth factor beta receptor antagonists; Proto oncogene protein c ret inhibitors; Proto oncogene protein c-kit inhibitors; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Prostate cancer

Most Recent Events

  • 22 May 2017 Pfizer suspends recruitment in a phase-I trial in Prostate cancer (Hormone refractory, Second-line therapy or greater) in USA (NCT02616185)
  • 30 Dec 2015 Phase-I clinical trials in Prostate cancer (Hormone refractory, Second-line therapy or greater) in USA (Parenteral)
  • 01 Dec 2015 Preclinical trials in Prostate cancer in USA (Parenteral) before December 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top